Cargando…

Association Between SGLT2is and Cardiovascular and Respiratory Diseases: A Meta-Analysis of Large Trials

The association between sodium-glucose cotransporter 2 inhibitors (SGLT2is) and various cardiovascular and respiratory diseases is unestablished. This meta-analysis aimed to explore whether use of SGLT2is is significantly associated with the occurrences of 80 types of cardiovascular diseases and 55...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Dao-Gen, Qiu, Mei, Duan, Xue-Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350118/
https://www.ncbi.nlm.nih.gov/pubmed/34381370
http://dx.doi.org/10.3389/fphar.2021.724405
_version_ 1783735685350424576
author Yin, Dao-Gen
Qiu, Mei
Duan, Xue-Yan
author_facet Yin, Dao-Gen
Qiu, Mei
Duan, Xue-Yan
author_sort Yin, Dao-Gen
collection PubMed
description The association between sodium-glucose cotransporter 2 inhibitors (SGLT2is) and various cardiovascular and respiratory diseases is unestablished. This meta-analysis aimed to explore whether use of SGLT2is is significantly associated with the occurrences of 80 types of cardiovascular diseases and 55 types of respiratory diseases. Large randomized trials of SGLT2is were included in analysis. Meta-analysis was conducted to synthesize risk ratio (RR) and 95% confidence interval (CI). Nine large trials were included in analysis. Compared to placebo, SGLT2is were associated with the reduced risks of 9 types of cardiovascular diseases (e.g., atrial fibrillation [RR 0.78, 95% CI 0.67-0.91], bradycardia [RR 0.60, 95% CI 0.40-0.89], and hypertensive emergency [RR 0.29, 95% CI 0.12-0.72]) and 11 types of respiratory diseases (e.g., chronic obstructive pulmonary disease [RR 0.77, 95% CI 0.61-0.97], asthma [RR 0.57, 95% CI 0.35-0.95], and sleep apnoea syndrome [RR 0.36, 95% CI 0.15-0.87]). The results of random-effects meta-analysis were similar with those of fixed-effects meta-analysis. No heterogeneity or only little heterogeneity was found in most meta-analyses. No publication bias was observed in most of the meta-analyses conducted in this study. SGLT2is were not significantly associated with the other 115 cardiovascular and respiratory diseases. SGLT2is are associated with the reduced risks of 9 types of cardiovascular diseases (e.g., atrial fibrillation, bradycardia, and hypertensive emergency) and 11 types of respiratory diseases (e.g., chronic obstructive pulmonary disease, asthma, and sleep apnoea syndrome). This proposes the potential of SGLT2is to be used for prevention of these cardiovascular and respiratory diseases.
format Online
Article
Text
id pubmed-8350118
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83501182021-08-10 Association Between SGLT2is and Cardiovascular and Respiratory Diseases: A Meta-Analysis of Large Trials Yin, Dao-Gen Qiu, Mei Duan, Xue-Yan Front Pharmacol Pharmacology The association between sodium-glucose cotransporter 2 inhibitors (SGLT2is) and various cardiovascular and respiratory diseases is unestablished. This meta-analysis aimed to explore whether use of SGLT2is is significantly associated with the occurrences of 80 types of cardiovascular diseases and 55 types of respiratory diseases. Large randomized trials of SGLT2is were included in analysis. Meta-analysis was conducted to synthesize risk ratio (RR) and 95% confidence interval (CI). Nine large trials were included in analysis. Compared to placebo, SGLT2is were associated with the reduced risks of 9 types of cardiovascular diseases (e.g., atrial fibrillation [RR 0.78, 95% CI 0.67-0.91], bradycardia [RR 0.60, 95% CI 0.40-0.89], and hypertensive emergency [RR 0.29, 95% CI 0.12-0.72]) and 11 types of respiratory diseases (e.g., chronic obstructive pulmonary disease [RR 0.77, 95% CI 0.61-0.97], asthma [RR 0.57, 95% CI 0.35-0.95], and sleep apnoea syndrome [RR 0.36, 95% CI 0.15-0.87]). The results of random-effects meta-analysis were similar with those of fixed-effects meta-analysis. No heterogeneity or only little heterogeneity was found in most meta-analyses. No publication bias was observed in most of the meta-analyses conducted in this study. SGLT2is were not significantly associated with the other 115 cardiovascular and respiratory diseases. SGLT2is are associated with the reduced risks of 9 types of cardiovascular diseases (e.g., atrial fibrillation, bradycardia, and hypertensive emergency) and 11 types of respiratory diseases (e.g., chronic obstructive pulmonary disease, asthma, and sleep apnoea syndrome). This proposes the potential of SGLT2is to be used for prevention of these cardiovascular and respiratory diseases. Frontiers Media S.A. 2021-07-26 /pmc/articles/PMC8350118/ /pubmed/34381370 http://dx.doi.org/10.3389/fphar.2021.724405 Text en Copyright © 2021 Yin, Qiu and Duan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Yin, Dao-Gen
Qiu, Mei
Duan, Xue-Yan
Association Between SGLT2is and Cardiovascular and Respiratory Diseases: A Meta-Analysis of Large Trials
title Association Between SGLT2is and Cardiovascular and Respiratory Diseases: A Meta-Analysis of Large Trials
title_full Association Between SGLT2is and Cardiovascular and Respiratory Diseases: A Meta-Analysis of Large Trials
title_fullStr Association Between SGLT2is and Cardiovascular and Respiratory Diseases: A Meta-Analysis of Large Trials
title_full_unstemmed Association Between SGLT2is and Cardiovascular and Respiratory Diseases: A Meta-Analysis of Large Trials
title_short Association Between SGLT2is and Cardiovascular and Respiratory Diseases: A Meta-Analysis of Large Trials
title_sort association between sglt2is and cardiovascular and respiratory diseases: a meta-analysis of large trials
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350118/
https://www.ncbi.nlm.nih.gov/pubmed/34381370
http://dx.doi.org/10.3389/fphar.2021.724405
work_keys_str_mv AT yindaogen associationbetweensglt2isandcardiovascularandrespiratorydiseasesametaanalysisoflargetrials
AT qiumei associationbetweensglt2isandcardiovascularandrespiratorydiseasesametaanalysisoflargetrials
AT duanxueyan associationbetweensglt2isandcardiovascularandrespiratorydiseasesametaanalysisoflargetrials